Video: FDA's TAVI panel in review with Dr. Michael Gibson

Justine Varieur Cadet | | Cardiovascular Business | Interventional Cardiology
Click to play
Video: Justine Cadet speaks with C. Michael Gibson, MD
Interventional Cardiologist
Beth Israel Deaconess Medical Center
Boston, Mass.
BOSTON--Justine Cadet from Cardiovascular Business sat down with C. Michael Gibson, MD, interventional cardiologist at the Beth Israel Deaconess Medical Center in Boston, to discuss the FDA’s Circulatory System Devices Panel, which convened July 20 in Bethesda, Md., and recommended approval of the Sapien transcatheter heart valve (Edwards Lifesciences), based on the results of the Cohort B of the PARTNER trial.

The discussion traversed such topics as the changes to the requested indication, the safety considerations, the final vote and the post-approval studies.

Justine Varieur Cadet

Related Content

Surgery outperforms PCI in NSTEMI patients with multivessel CAD
Boston Scientific enters IVL arms race with acquisition worth up to $664M
FDA sees value in no-implant heart failure device
Radial secondary access during TAVR limits complications
Medtronic’s Harmony TPVR system gains CE mark approval
History made: Young child treated with new heart device for very first time

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.